Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01755767




Registration number
NCT01755767
Ethics application status
Date submitted
19/12/2012
Date registered
24/12/2012
Date last updated
6/04/2021

Titles & IDs
Public title
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
Scientific title
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Secondary ID [1] 0 0
2012-003308-10
Secondary ID [2] 0 0
ARQ197-A-U303
Universal Trial Number (UTN)
Trial acronym
METIV-HCC
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatocellular Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Liver

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Tivantinib
Treatment: Drugs - Placebo

Experimental: Tivantinib 240 mg BID Cohort - The tivantinib dosage of 240 mg tablets administered by mouth twice daily (BID), once in the morning and once in the evening, with food, for a total daily dose of 480 mg.

Experimental: Tivantinib 120 mg BID Cohort - Tivantinib 120 mg is administered by oral tablet BID, once in the morning and once in the evening, with food, for a total daily dose of 240 mg (amended dosing group; primary analysis group).

Placebo Comparator: Placebo Matching 240 mg BID Cohort - Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.

Placebo Comparator: Placebo Matching 120 mg BID Cohort - Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.


Treatment: Drugs: Tivantinib
Tivantinib tablets

Treatment: Drugs: Placebo
Matching placebo tablets
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Median Overall Survival (OS) Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy
Timepoint [1] 0 0
within 36 months
Primary outcome [2] 0 0
Overall Survival (OS) Rate At Different Time Points Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy
Timepoint [2] 0 0
within 36 months
Secondary outcome [1] 0 0
Progression-free Survival Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy (ITT Population)
Timepoint [1] 0 0
within 10 months
Secondary outcome [2] 0 0
Treatment-Emergent Adverse Events Reported (>20% in Tivantinib Cohort) Following Treatment With Tivantinib Compared With Placebo in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy
Timepoint [2] 0 0
Baseline to 30 days after last dose, up to approximately 4 years
Secondary outcome [3] 0 0
Treatment-Emergent Adverse Events Reported (>20% in Tivantinib Cohort) Following Treatment With Tivantinib Compared With Placebo in Participants With MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Systemic Therapy
Timepoint [3] 0 0
Baseline to 30 days after last dose, up to approximately 4 years

Eligibility
Key inclusion criteria
- Histologically confirmed HCC that is inoperable (where surgery is not indicated due to
disease extension, co-morbidities, or other technical reasons), and not eligible for
local therapy

- MET Diagnostic-High tissue reported by the central authorized laboratory using
archival or recent biopsy tumor samples

- Received at least 4 weeks of one prior sorafenib containing systemic therapy and then
experienced documented radiographic disease progression; or inability to tolerate
prior therapy received for at least a minimum period of time.

- Discontinued prior systemic treatment or any investigational drug for at least 2 weeks
(14 days) or for at least 3 weeks for IV anti-cancer drugs, prior to the study
randomization

- Local or loco-regional therapy (i.e., surgery, radiation therapy, hepatic arterial
embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol
injection, or cryoablation) must have been completed >= 4 weeks prior to randomization

- Measurable disease as defined by the RECIST v1.1.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- More than 1 prior systemic regimen (prior MET inhibitors/antibodies are not allowed;
experimental systemic therapy for inoperable HCC given before or after sorafenib
counts as separate regimen and is not allowed)

- Child-Pugh B-C cirrhotic status based on clinical findings and laboratory results

- Previous or concurrent cancer that is distinct from HCC in primary site or histology,
EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, and superficial
bladder tumors. Any cancer curatively treated more than 3 years prior to enrollment is
permitted.

- History of congestive heart failure defined as Class II to IV per New York Heart
Association (NYHA) classification within 6 months prior to study entry; active
coronary artery disease (CAD); clinically significant bradycardia or other
uncontrolled, cardiac arrhythmia defined as greater than or equal to Grade 3 according
to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events
(CTCAE), or uncontrolled hypertension; myocardial infarction occurring within 6 months
prior to study entry (myocardial infarction occurring more than 6 months prior to
study entry is permitted)

- Active clinically serious infections defined as >= Grade 3 according to NCI CTCAE

- Any medical, psychological, or social conditions, particularly if unstable, including
substance abuse, that may, in the opinion of the Investigator, interfere with the
subject's safety or participation in the study, protocol compliance, or evaluation of
the study results

- Known human immunodeficiency virus (HIV) infection

- Blood or albumin transfusion within 5 days prior to the blood draw being used to
confirm eligibility

- Concomitant interferon therapy or therapies for active Hepatitis C virus (HCV)
infection

- Pregnancy or breast-feeding

- History of liver transplant

- Inability to swallow oral medications

- Clinically significant gastrointestinal bleeding occurring <= 4 weeks prior to
randomization

- Pleural effusion or clinically evident (visible or palpable) ascites

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/12/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
31/07/2017
Sample size
Target
Accrual to date
Final
383
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Recruitment hospital [1] 0 0
- Camperdown
Recruitment hospital [2] 0 0
- Heidelberg
Recruitment hospital [3] 0 0
- Melbourne
Recruitment hospital [4] 0 0
- Nedlands
Recruitment postcode(s) [1] 0 0
- Camperdown
Recruitment postcode(s) [2] 0 0
- Heidelberg
Recruitment postcode(s) [3] 0 0
- Melbourne
Recruitment postcode(s) [4] 0 0
- Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maine
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Washington
Country [18] 0 0
Argentina
State/province [18] 0 0
Buenos Aires
Country [19] 0 0
Argentina
State/province [19] 0 0
Caba
Country [20] 0 0
Argentina
State/province [20] 0 0
Pilar
Country [21] 0 0
Austria
State/province [21] 0 0
Graz
Country [22] 0 0
Austria
State/province [22] 0 0
Innsbruck
Country [23] 0 0
Austria
State/province [23] 0 0
Linz
Country [24] 0 0
Austria
State/province [24] 0 0
Wien
Country [25] 0 0
Belgium
State/province [25] 0 0
Brussels
Country [26] 0 0
Belgium
State/province [26] 0 0
Ghent
Country [27] 0 0
Belgium
State/province [27] 0 0
Leuven
Country [28] 0 0
Belgium
State/province [28] 0 0
Liege
Country [29] 0 0
Brazil
State/province [29] 0 0
RS
Country [30] 0 0
Brazil
State/province [30] 0 0
SP
Country [31] 0 0
Brazil
State/province [31] 0 0
Barretos
Country [32] 0 0
Brazil
State/province [32] 0 0
Rio de Janeiro
Country [33] 0 0
Canada
State/province [33] 0 0
British Columbia
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
France
State/province [35] 0 0
Amiens Cedex 1
Country [36] 0 0
France
State/province [36] 0 0
Bordeaux Cedex
Country [37] 0 0
France
State/province [37] 0 0
Caen Cedex 09
Country [38] 0 0
France
State/province [38] 0 0
Clichy
Country [39] 0 0
France
State/province [39] 0 0
Creteil
Country [40] 0 0
France
State/province [40] 0 0
Grenoble
Country [41] 0 0
France
State/province [41] 0 0
Lille Cedex
Country [42] 0 0
France
State/province [42] 0 0
Marseille Cedex 09
Country [43] 0 0
France
State/province [43] 0 0
Montpellier
Country [44] 0 0
France
State/province [44] 0 0
Paris Cedex 12
Country [45] 0 0
France
State/province [45] 0 0
Paris Cedex
Country [46] 0 0
France
State/province [46] 0 0
Reims Cedex
Country [47] 0 0
France
State/province [47] 0 0
Rennes Cedex
Country [48] 0 0
France
State/province [48] 0 0
Toulouse Cedex 09
Country [49] 0 0
France
State/province [49] 0 0
Villejuif Cedex
Country [50] 0 0
Germany
State/province [50] 0 0
Aachen
Country [51] 0 0
Germany
State/province [51] 0 0
Berlin
Country [52] 0 0
Germany
State/province [52] 0 0
Bonn
Country [53] 0 0
Germany
State/province [53] 0 0
Duesseldorf
Country [54] 0 0
Germany
State/province [54] 0 0
Essen
Country [55] 0 0
Germany
State/province [55] 0 0
Frankfurt am Main
Country [56] 0 0
Germany
State/province [56] 0 0
Hamburg
Country [57] 0 0
Germany
State/province [57] 0 0
Hannover
Country [58] 0 0
Germany
State/province [58] 0 0
Heidelberg
Country [59] 0 0
Germany
State/province [59] 0 0
Leipzig
Country [60] 0 0
Germany
State/province [60] 0 0
Magdeburg
Country [61] 0 0
Germany
State/province [61] 0 0
Mainz
Country [62] 0 0
Germany
State/province [62] 0 0
Muenchen
Country [63] 0 0
Germany
State/province [63] 0 0
Munich
Country [64] 0 0
Germany
State/province [64] 0 0
Regensburg
Country [65] 0 0
Germany
State/province [65] 0 0
Tuebingen
Country [66] 0 0
Germany
State/province [66] 0 0
Ulm
Country [67] 0 0
Germany
State/province [67] 0 0
Wuerzburg
Country [68] 0 0
Italy
State/province [68] 0 0
Forli-Cesena
Country [69] 0 0
Italy
State/province [69] 0 0
Milano
Country [70] 0 0
Italy
State/province [70] 0 0
Torino
Country [71] 0 0
Italy
State/province [71] 0 0
Benevento
Country [72] 0 0
Italy
State/province [72] 0 0
Bergamo
Country [73] 0 0
Italy
State/province [73] 0 0
Bologna
Country [74] 0 0
Italy
State/province [74] 0 0
Catania
Country [75] 0 0
Italy
State/province [75] 0 0
Firenze
Country [76] 0 0
Italy
State/province [76] 0 0
Modena
Country [77] 0 0
Italy
State/province [77] 0 0
Napoli
Country [78] 0 0
Italy
State/province [78] 0 0
Padova
Country [79] 0 0
Italy
State/province [79] 0 0
Parma
Country [80] 0 0
Italy
State/province [80] 0 0
Pavia
Country [81] 0 0
Italy
State/province [81] 0 0
Pisa
Country [82] 0 0
Italy
State/province [82] 0 0
Reggio Emilia
Country [83] 0 0
Italy
State/province [83] 0 0
Roma
Country [84] 0 0
Italy
State/province [84] 0 0
Turin
Country [85] 0 0
Netherlands
State/province [85] 0 0
Amsterdam
Country [86] 0 0
New Zealand
State/province [86] 0 0
Auckland
Country [87] 0 0
Portugal
State/province [87] 0 0
Lisboa
Country [88] 0 0
Portugal
State/province [88] 0 0
Porto
Country [89] 0 0
Portugal
State/province [89] 0 0
Vila Real
Country [90] 0 0
Spain
State/province [90] 0 0
A Coruña
Country [91] 0 0
Spain
State/province [91] 0 0
Asturias
Country [92] 0 0
Spain
State/province [92] 0 0
Madrid
Country [93] 0 0
Spain
State/province [93] 0 0
Navarra
Country [94] 0 0
Spain
State/province [94] 0 0
Alicante
Country [95] 0 0
Spain
State/province [95] 0 0
Barcelona
Country [96] 0 0
Spain
State/province [96] 0 0
Cordoba
Country [97] 0 0
Spain
State/province [97] 0 0
Sabadell
Country [98] 0 0
Spain
State/province [98] 0 0
Santander
Country [99] 0 0
Spain
State/province [99] 0 0
Valencia
Country [100] 0 0
Spain
State/province [100] 0 0
Zaragoza
Country [101] 0 0
Sweden
State/province [101] 0 0
Gothenburg
Country [102] 0 0
Sweden
State/province [102] 0 0
Stockholm
Country [103] 0 0
Switzerland
State/province [103] 0 0
Bern
Country [104] 0 0
Switzerland
State/province [104] 0 0
Zurich

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Daiichi Sankyo
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine if tivantinib (ARQ 197) is effective in treating
patients with MET diagnostic-high hepatocellular carcinoma (liver cancer) who have already
been treated once with another therapy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01755767
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Global Clinical Leader
Address 0 0
Daiichi Sankyo
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01755767